Home › Trial NCT06040320
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
- Trial IDNCT06040320
- StatusActive Not Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorWashington University School of Medicine
- Enrollment12
- Start date2023-10-04
- ConditionsPost-transplant Lymphoproliferative Disorder
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.